- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.10. | Biotechs brush off sector headwinds in venture financing rebound | ||
| 23.10. | Alkermes to acquire Avadel for $2.1bn | ||
| 22.10. | Galapagos to shutter cell and gene therapy unit | ||
| 22.10. | Novo Nordisk sees board shakeup amid member exodus | ||
| 22.10. | Ventus and Genentech partner for small-molecule medicine discovery | ||
| 22.10. | Health Canada conditionally approves Gilead Sciences' Lyvdelzi for PBC | ||
| 21.10. | ESMO 2025: Merck KGaA's ADC leapfrogs to Phase III in colorectal cancer | ||
| 21.10. | Gibson, Dunn & Crutcher, White & Case top MEA legal advisers in Q1-Q3 2025 | ||
| 21.10. | ESMO 2025: MSD's ADC leapfrogs to Phase III in colorectal cancer | ||
| 21.10. | MSD initiates construction on $3bn Virginia drug manufacturing site | ||
| 21.10. | Lundbeck and Contera partner for oligonucleotide-based medicines | ||
| 21.10. | FDA approves Roche's Gazyva for lupus nephritis | ||
| 20.10. | FDA approves Glaukos' Epioxa as incision-free corneal disease treatment | ||
| 20.10. | ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory | ||
| 20.10. | Infertility treatment heads first drugs on FDA's new priority review scheme | ||
| 20.10. | FDA greenlight for Roche's Alzheimer's disease test sparks care paradigm shift | ||
| 20.10. | ESMO 2025: Eli Lilly's Verzenio extends survival in high-risk early breast cancer | ||
| 17.10. | Market dynamics for generics must change amid ANDA pilot debut | ||
| 17.10. | Adcytherix gains $122m to propel ADC development | ||
| 17.10. | EMD Serono partners US government to widen IVF access | ||
| 16.10. | AstraZeneca doubles Lokelma output with $445m Texas plant expansion | ||
| 16.10. | Novo Nordisk snaps up Omeros' rare disease asset for up to $2.1bn | ||
| 16.10. | Bavarian Nordic's shareholders and board in standoff amid takeover offer | ||
| 16.10. | Tubulis closes $361m in Series C to advance cancer treatment | ||
| 16.10. | Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .